1-2 of 2
David Alejandro Veron, MD
Close
Sort by
Journal Articles

Risk-Adapted Therapy with ABVD for Low- and Intermediate-Risk Patients and Oepa-Copdac for High Risk Patients Plus Involved-Field Radiation Therapy (IFRT) Based on Prognosis at Diagnosis and Early Response: Results from Pediatric Argentinian Collaborative Group Gatla Study for Children and Adolescents with Hodgkin Lymphoma

David Alejandro Veron, MD, Patricia Streitenberger, MD, Cecilia Riccheri, MD, Monica Matus, MD, Pedro Negri Aranguren, MD, Maria Alejandra Costa, MD, Nestor Alfredo Rossi, MD, Elizabeth Hiramatsu, MD, Maria Alejandra Cedola, MD, María Constanza Drozdowski, MD, Sandra Borchichi, MD, Marcelo Coirini, MD, María Cecilia Murray, MD, Karina D'Aloi, MD, Carlos Holmann, MD, Matilde Gomel, MD, Gisela Drago, MD, Horacio Daniel Caferri, MD, Maria Angelica Fernandez Barbieri, MD, Mara Villamil, MD, Claudia Mabel Ruiz, MD, Sandra Ethel Zirone, MD, Monica Makiya, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13.
https://doi.org/10.1182/blood-2020-135945
Published: 2020
Journal Articles

Comparison of Outcome of Adolescents with Newly Diagnosed Hodgkin Lymphoma (HL) in Argentina, Treated within a Pediatric Vs an Adults Clinical Trial : Experience of the Gatla Group

David Alejandro Veron, MD, Patricia Streitenberger, MD, Daniel Freigeiro, MD, Astrid Pavlovsky, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5175.
https://doi.org/10.1182/blood.V130.Suppl_1.5175.5175
Published: 2017